Anti-CDKN2C Antibody

Raised in rabbit as a polyclonal IgG reagent against CDKN2C (also known as p18-INK4c), this unconjugated primary antibody binds the cyclin-dependent kinase inhibitor that governs the G1-to-S phase checkpoint by antagonizing CDK4 and CDK6 complexes. The reagent from Antibodies.com is validated for western blot and immunohistochemistry workflows on human and mouse specimens, making it a practical tool for studies of tumor suppression, hematopoiesis, and B-cell lymphoma biology where CDKN2C loss or silencing is a frequent event.

Each vial delivers 100 µl of antibody in a single-use aliquot format suitable for standard immunodetection protocols, including formalin-fixed paraffin-embedded tissue sections and whole-cell lysate preparations. Polyclonal coverage broadens epitope recognition relative to monoclonal alternatives, which is helpful when probing native CDK4/6 complexes or when target abundance is variable across tissues. Researchers investigating cell cycle exit during terminal differentiation, or screening for CDKN2C deletion in lymphoid malignancies, can deploy this reagent across blotting and staining workflows with confidence in cross-species reactivity.